Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. Sonowal H, Rice WG, Howell SB. PLoS One 2023;18:e0277003.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sonowal H, Rice WG, Howell SB. Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PLoS One 2023;18:e0277003.
PMID: 36888611